A Victory for Cannabis Farming as Agriculture in Michigan

The Legal Impact of Marijuana Reclassification in Cannabis Law

On May 6, 2024, the Drug Enforcement Administration (DEA) made a historic decision: it accepted the US Department of Health and Human Services’ recommendation to reclassify marijuana from Schedule I to Schedule III controlled substance. This shift has far-reaching implications for the legal status of cannabis, impacting taxation, banking, employment, regulation, and more.

Reclassification places marijuana in the company of substances like acetaminophen with codeine, ketamine, and testosterone, recognizing its accepted medical use and low potential for abuse. While federal legalization remains elusive, this move acknowledges the evolving understanding of marijuana’s therapeutic properties.

Despite federal reclassification, state marijuana laws remain unchanged in the 24 states, two territories, and Washington D.C. where cannabis is legal for adult recreational use, and the 38 states allowing medical cannabis. However, businesses stand to benefit from significant tax breaks under the Internal Revenue Code, as reclassification would permit deductions for business expenses, potentially saving hundreds of thousands or even millions of dollars.

Marijuana reclassification from Schedule I to Schedule III would represent a significant step in reshaping cannabis law.

Moreover, reclassification could facilitate access to major stock exchanges, attracting investment capital for cannabis companies. Yet, challenges persist in the banking sector due to federal illegality. Cannabis businesses still face obstacles in accessing basic financial services, operating largely in cash to avoid legal entanglements.

While federal reclassification marks progress, cannabis remains illegal under federal law, creating discrepancies with state laws. For example, in Michigan, despite recreational marijuana legalization, employers retain the right to enforce drug policies and can refuse employment or terminate individuals for violating workplace rules.

Rescheduling marijuana to Schedule III raises regulatory considerations, potentially subjecting medical cannabis to increased FDA oversight. This could impact licensing, distribution, and compliance protocols, necessitating a review of existing regulatory frameworks by cannabis businesses.

However, reclassification does not address critical issues such as bankruptcy protection or federal trademark registrations for cannabis companies. Cannabis businesses remain ineligible for bankruptcy protection under current law, and federal trademark registrations are unavailable due to marijuana’s federal illegality.

While reclassification signifies progress for cannabis recognition, its full implications remain uncertain pending further regulatory and legal developments. The proposal must undergo review by the Office of Management and Budget and a 60-day public comment period, potentially leading to further evaluation by an Administrative Law Judge.

Marijuana reclassification from Schedule I to Schedule III represents a significant step in reshaping cannabis law. However, navigating the legal landscape requires vigilance and adaptability as businesses and regulators respond to evolving regulations and market dynamics.